It’s time for a new era of public health—where vaccines are seen as both a scientific triumph and a shared commitment to well ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm lowered its rating on MRNA to "neutral" from "buy," and nearly halved its price ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

Ahead of his confirmation hearing this week, Robert F. Kennedy Jr., President Donald Trump’s nominee for HHS Secretary, has ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA ...

Even so, broadening the range of trials’ participants can be practically useful, because they may lead to new medical ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it.

When you buy through our links, we may earn a commission. Learn more› By Caira Blackwell and Joanne Chen If you’re a side-sleeper, congratulations! According to the Mayo Clinic, side sleeping ...

The government is urging the public to get vaccinated against influenza and Covid-19 before the Lunar New Year holiday, which ...

And regular polling carried out by YouGov suggests adults are increasingly likely to say that vaccines have harmful side ...